Celgene Receives Positive CHMP Opinion For OTEZLA, The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis
November 21, 2014 at 06:02 AM EST
Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines ...